Lymphocyte Toxicity After PRRT
| Patient blood identifier | Baseline PBL count before first treatment (cells × 103/mm3) | PBL counts before indicated treatment* (cells × 103/mm3) | PBL count 2 wk after indicated treatment* (cells × 103/mm3) | PBL reduction (%) before indicated treatment to 2 wk after indicated treatment | PBL reduction (%) between baseline and 2 wk after indicated treatment |
| P1.1 | 1.6 | 1.6 | 0.6 | 63 | 63 |
| P1.2 | 1.6 | 0.8 | 0.5 | 38 | 69 |
| P1.3 | 1.6 | 1.0 | 0.5 | 50 | 69 |
| P2.2 | 1.4 | 1.0 | 0.5 | 50 | 64 |
| P2.3 | 1.4 | 0.5 | 0.4 | 20 | 71 |
| P2.5 | 1.4 | 0.5 | 0.3 | 40 | 79 |
| P3.3 | 2.9 | 1.8 | 0.9 | 50 | 69 |
| P3.4 | 2.9 | 1.1 | 0.9 | 18 | 69 |
| P4.1 | 1.2 | 1.2 | 0.8 | 33 | 33 |
| P5.1 | 1.5 | 1.5 | 0.8 | 47 | 47 |
| P6.1 | 2.3 | 2.3 | 0.9 | 61 | 61 |
| P7.3 | 2.5 | 0.5 | 0.3 | 40 | 88 |
| P8.3 | 1.7 | 0.9 | 0.6 | 33 | 65 |
| P9.3 | 1.3 | 0.9 | 0.4 | 56 | 70 |
| P10.5 | 1.9 | 1.2 | 0.6 | 50 | 68 |
| P11.6 | 2.3 | 1.7 | 1.5 | 12 | 34 |
↵* “Indicated treatment” refers to treatment cycle number denoted by last digit in patient blood identifier.
Patients are numbered from P1 to P11 followed by treatment cycle number.